Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03912337 · ClinicalTrials.gov registry record · Phase 4
Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine
A Phase 4 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
NCT03912337: Clinical Trial Phase 4 study, sponsored by Amgen.
NCT03912337 is a Phase 4 study that was terminated before completion, run by Amgen. The registered enrollment target is 29 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03912337, a Phase 4 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
Study Summary
To evaluate the effect of erenumab compared to placebo on disability in employed subjects with episodic migraine (EM) who have previously failed 1 or more migraine preventive treatments.
Primary Outcome
The modified MIDAS Questionnaire is a 5-item questionnaire that measures headache-related disability as lost time from paid work or school, housework, and non-work (family, social, and leisure) activities. Participants provided the number of productive days lost or productivity reduced by half or more over the past month due to headache (item score range from 0 to 31). Productive days lost counted in items 1 and 3 were not included for items 2 and 4, respectively. The 5 item scores were summed t
Interventions
- DRUG Placebo
- DRUG Erenumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2021-07-28 |
| Phase | Phase 4 |
Why NCT03912337 stopped before completion
NCT03912337 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03912337 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03912337 about?
NCT03912337 is a clinical study titled "Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine". To evaluate the effect of erenumab compared to placebo on disability in employed subjects with episodic migraine (EM) who have previously failed 1 or more migraine preventive treatments.
What is the current status of trial NCT03912337?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2019-12-04. Estimated completion is 2021-07-28.
What interventions are being tested in trial NCT03912337?
The interventions under investigation include: Placebo (DRUG), Erenumab (DRUG).
Who is sponsoring clinical trial NCT03912337?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03912337's enrollment target sits among peer trials
29 1634th of 2000 higher than 366 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI